Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Phase 1 trial records — page 6

226 records at phase 1.

Showing 0 records on this page

Records

226 documents · page 6 of 10

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
AWARD-1-DDIprogramme recordDulaglutidePhase 1ReportedRandomised crossover2014Very low
KISS-IVF-TRIGGER-DDIprogramme recordKisspeptin-10Phase 1ReportedRandomised crossover2014Very low
AWARD-1-HEPATIC-IMPprogramme recordDulaglutidePhase 1ReportedPhase 1 ascending dose2014Very low
KISS-IVF-TRIGGER-HEPATIC-IMPprogramme recordKisspeptin-10Phase 1ReportedPhase 1 ascending dose2014Very low
AWARD-1-RENAL-IMPprogramme recordDulaglutidePhase 1ReportedPhase 1 ascending dose2014Very low
KISS-IVF-TRIGGER-RENAL-IMPprogramme recordKisspeptin-10Phase 1ReportedPhase 1 ascending dose2014Very low
AWARD-1-PKprogramme recordDulaglutidePhase 1ReportedPhase 1 ascending dose2014Very low
KISS-IVF-TRIGGER-PKprogramme recordKisspeptin-10Phase 1ReportedPhase 1 ascending dose2014Very low
GETGOAL-L-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-L-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-L-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-L-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-DUO-1-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-M-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
TB4-PH1-CARDIACThymosin beta-4Phase 1ReportedPhase 1 ascending dose2012Very low
STEPS-DDIprogramme recordTeduglutidePhase 1ReportedRandomised crossover2012Very low
TB4-PH1-CARDIAC-QOLprogramme recordThymosin beta-4Phase 1ReportedRandomised, double-blind, placebo-controlled2012Very low
STEPS-HEPATIC-IMPprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose2012Very low
TB4-PH1-CARDIAC-BODY-COMPprogramme recordThymosin beta-4Phase 1ReportedRandomised, double-blind, placebo-controlled2012Very low
STEPS-RENAL-IMPprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose2012Very low
STEPS-PKprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose2012Very low

page 6 of 10

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.